126 related articles for article (PubMed ID: 25268091)
1. Agents for refractory/relapsed acute lymphocytic leukemia in adults.
Qian LR; Fu W; Shen JL
Eur Rev Med Pharmacol Sci; 2014; 18(17):2465-74. PubMed ID: 25268091
[TBL] [Abstract][Full Text] [Related]
2. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
[TBL] [Abstract][Full Text] [Related]
3. GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia.
Camera A; Annino L; Chiurazzi F; Fazi P; Cascavilla N; Fabbiano F; Marmont F; Di Raimondo F; Recchia A; Vignetti M; Rotoli B; Mandelli F
Haematologica; 2004 Feb; 89(2):145-53. PubMed ID: 15003889
[TBL] [Abstract][Full Text] [Related]
4. An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia.
Aldoss I; Pullarkat V; Patel R; Watkins K; Mohrbacher A; Levine AM; Douer D
Med Oncol; 2013 Dec; 30(4):744. PubMed ID: 24135867
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
Zhou K; Song Y; Zhang Y; Wei X; Fu Y; Yu F; Zhou H; Liu X; Zhou J; Fang B
Leuk Res; 2017 Nov; 62():29-33. PubMed ID: 28982056
[TBL] [Abstract][Full Text] [Related]
6. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial.
Martino R; Bellido M; Brunet S; Altés A; Sureda A; Guárdia R; Aventín A; Nomdedéu JF; Domingo-Albós A; Sierra J
Haematologica; 1999 Jun; 84(6):505-10. PubMed ID: 10366793
[TBL] [Abstract][Full Text] [Related]
7. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review.
Dombret H; Thomas X; Chevallier P; Nivot E; Reitan J; Barber B; Barlev A; Mohty M
J Med Econ; 2016 Nov; 19(11):1034-1039. PubMed ID: 27207188
[TBL] [Abstract][Full Text] [Related]
8. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
Dinner S; Lee D; Liedtke M
Leuk Lymphoma; 2014 Aug; 55(8):1715-24. PubMed ID: 24251864
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
Ronson A; Tvito A; Rowe JM
Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
[TBL] [Abstract][Full Text] [Related]
10. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
12. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
13. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
14. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
[TBL] [Abstract][Full Text] [Related]
15. Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Cui JK; Xiao Y; You Y; Shi W; Li Q; Luo Y; Jiang L; Zhong ZD
J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):693-698. PubMed ID: 29058281
[TBL] [Abstract][Full Text] [Related]
16. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
17. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
Bao L; Jiang B; Huang XJ; Wang DB; Qiu JY; Lu XJ; Lu J; Shi HX; Wang FR; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 37(4):355-7. PubMed ID: 16086050
[TBL] [Abstract][Full Text] [Related]
19. Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium.
Wang ES; Jabbour EJ; Douer D
Clin Adv Hematol Oncol; 2016 Mar; 14(3 Suppl 4):1-23. PubMed ID: 27007406
[TBL] [Abstract][Full Text] [Related]
20. CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
Wei G; Hu Y; Pu C; Yu J; Luo Y; Shi J; Cui Q; Wu W; Wang J; Xiao L; Wu Z; Huang H
Ann Hematol; 2018 May; 97(5):781-789. PubMed ID: 29417201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
